Plain-English translation of NCT07594925 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining short-course radiation therapy with chemotherapy and an immune-boosting drug called can better treat locally advanced rectal cancer. Researchers want to see if adding — a medication that helps your immune system fight cancer — alongside standard chemotherapy improves how well the treatment works and what happens after surgery.
Standard treatment for locally advanced rectal cancer works reasonably well, but many patients still experience cancer recurrence or poor long-term survival. This trial explores whether the new treatment can provide better tumor shrinkage and longer-term protection by harnessing your body's own immune system to fight the cancer.
You likely qualify if…
You likely don't qualify if…
If you enroll, you would first receive short-course radiation therapy combined with four cycles of chemotherapy and the immune medication over several weeks. After surgery to remove the cancer, you would receive additional chemotherapy and immune medication cycles, followed by ongoing immune therapy maintenance for up to one year total. Throughout the trial, you'll have regular medical visits, blood tests, and imaging scans to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China